Acute and tardive dystonia

Drug-Induced Movement Disorders

Volumn , Issue , 2004, Pages 111-128

  Bhatt, Mohit ^a   Sethi, Kapil D ^b   Bhatia, Kailash ^c  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928071167     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Angle CR, McIntire MS. Persistent dystonia in a brain-damaged child after ingestion of phenothiazine. Pediatr Pharmacol Ther 1968; 73:124–126.
2. Arana GW, Goff DC, Baldessarini RJ, Keepers GA. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am, J. Psychiatry 1988; 25: 993–996.
3. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–1060.
4. Ayers JL, Dawson KP. Acute dystonic reactions in childhood. N.Z. Med. J 1980; 92:964–965.
5. Berg D, Becker G, Naumann M, Reiners K. Morphine in tardive and idiopathic dystonia. J Neural Transm 2001; 108:1035–1041.
6. Bhatia KP, Quinn NP, Marsden CD. Clinical features and natural history of axial predominant adult onset primary dystonia. J Neurol Neurosurg Psychiatry 1997; 63: 788–791.
7. Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. Secondary dystonia and the DYTI gene. Neurology 1997; 48:1571–1577.
8. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32:1335–1346.
9. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movements. Am. J. Psychiatry 1979; 136:317–320.
10. Carroll BJ, Curtis GC, Kokmen E. Paradoxical response of dopamine agonists in tardive dyskinesia. Am. J. Psychiatry 1977; 134:785–790.
11. Cavanaugh JJ, Finlayson RE. Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J. Clin. Psychiatry 1984; 45:356–357.
12. Channon RA. Schizophrenia. In: Flaherty JA, Davis JM, Janicak PG, Eds. Psychiatry: Diagnosis and Therapy. Norwalk. CT: Appleton and Lange, 1993:91–120.
13. Chiles JA. Extrapyramidal reactions in adolescents treated with high-potency antipsy-chotics. Am. J. Psychiaatry 1978; 135:239–240.
14. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149:1081–1085.
15. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000; 355:2220–2221.
16. Crane GE. Persistent dyskinesia. Br J Psychiatry 1973; 122:395–405.
17. Druckman R, Seelinger D, Thulin B. Chronic involuntary movements induced by phenothiazines. J Nerv Ment Dis 1962; 135:69–76.
18. Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964; 40:10–27.
19. Flaherty JA, Lahmeyer HW. Laryngeal-pharyngeal dystonia as a possible cause of asphyxia with haloperidol treatment. Am.J. Psychiatry 1978; 135:1414–1415.
20. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50:801–803.
21. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Mov Disorders 1994; 9:321–324.
22. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am. J. Psychiatry 1978; 135: 1232–1233.
23. Gardos G, Cole JO, Salomon M, Schniebolk S. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144:895–902.
24. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis. Acta Psychiatr Scand 1985; 71:488–494.
25. Gunal DI, Onultan O, Afsar N, Aktan S. Tardive dystonia associated with olanzapine therapy. Neurol Sci 2001; 22:331–332.
26. Gureje O. The significance of subtyping tardive dyskinesia: A study of prevalence and associated factors. Psychol Med 1989; 19:121–128.
27. Inada T, Yagi G, Kaijima K, Ohnishi K, Kamisada M, Rockhold RW. Clinical variants of tardive dyskinesia in Japan. Jpn J Psychiatry Neurol 1991; 45:67–71.
28. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Move Disord 1986; 1:193–208.
29. Keegan DL, Rajput AH. Drug induced dystonia tarda: Treatment with L-dopa. Dis Nerv Syst 1973; 34:167–169.
30. Keepers GA, Casey DE. Clinical management of acute neuroleptic-induced extrapyramidal syndromes. In: J.H. Masserman, Ed. Current Psychiatric Therapies. New York: Grune & Stratton, 1986:139–157.
31. Keepers GA, Casey DE. Predicitiors of neuroleptic-induced dystonia. J. Clin. Psychopharmacol 1987; 7:342–345.
32. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch. Gen. Psychiatry 1983; 40:492–496.
33. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36(5):827–830.
34. Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1992 Apr; 149(4):511–513.
35. Kleij Der Van FG, Vries De PA, Stassen PM, Sprenger HG, Gans RO. Acute dystonia due to metoclopramide: Increased risk in AIDS. Arch Intern Med 2002; 162(3): 358–359.
36. Klintenberg R, Gunne L, Andren PE. Tardive dyskinesia model in the common marmoset. Move Disord 2002; 17(2):360–365.
37. Kiriakakis V, Bhatia K, Quinn NP, Marsden CD. Botulinum toxin treatment of tardive syndromes [abstr]. Move Disord 1997; 12:2.
38. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia: A long term follow-up study of 107 cases. Brain 1998; 121:2053–2066.
39. Kurtz G, Kapfhammer HP, Peuker B. Pisa-syndrome unter Clozapintherapie. Nervenarzt 1993; 64:742–746.
40. Lieberman JA, Saltz BL, Johns CA, Pollock S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503–510.
41. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984;41:157–161.
42. Lucetti C, Bellini G, Nuti A, Bernardini S, Dell’Agnello G, Piccinni A, Maggi L, Manca L, Bonuccelli U. Treatment of patients with tardive dystonia with olanzapine. Clin Neuropharmacol 2002; 25:71–74.
43. Manji H, Howard RS, Millar DH, Hirsch NP, Carr L, Bhatia KP, Quinn NP, Marsden CD. Status dystonicus: The syndrome and its management. Brain 1998; 121: 243–252.
44. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980; 10:55–72.
45. Matsumoto RR, Hemstreet MK, Lai NL, Thurkauf A, De Costa BR, Rice KC, Hellewell SB, Bowen WD, Walker JM. Drug specificity of pharmacological dystonia. Pharmacol, Biochem Behav 1990; 36:151–151.
46. Matsumoto RR, Pouw B. Correlation between neuroleptic binding to sigma(1) and sigma(2) receptors and acute dystonic reactions. Eur J Pharmacol 2000; 4;401(2): 155–156.
47. McLean P, Casey DE. Tardive dyskinesia n an adolescent. Am J Psychiatry 1978; 135:969–971.
48. Medina C, Kramer MD, Kuland AA. Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions. JAMA 1962; 182:1127–1129.
49. Micheli F, Fernandez Pardal M, Gatto M, Asconape J, Giannaula R, Parera IC. Bruxism secondary to chronic antidopaminergic drug exposure. Clin Neuropharmacol 1993; 16:351–323.
50. Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Move Disord 1999; 14:873–874.
51. Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and idiopathic cervical dystonia. Move Disord 1998; 13:486–489.
52. Narendran R, Young CM, Pato MT. Possible resperidone-induced tardive dystonia. Ann Pharmacother 2000; 34:1487–1488.
53. Nealer R, Gerhardt S, Liebman JM. Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAnergic drugs on acute dyskinesia in the squirrel monkey. Psychopharmacology l984; 82:20–26.
54. Piecuch S, Thomas U, Shah BR. Acute dystonic reactions that fail to respond to diphenhydramine: Think of PCP. J Emerg Med 1999; 17(3):527.
55. Postolache TT, Londono JH, Halem RG, Newmark MD. Electroconvulsive therapy in tardive dystonia. Convuls Ther 1995; 11:275–279.
56. Pourcher E, Baruch P, Bouchard RH, Filteau MJ, Bergeron D. Neuroleptic associated tardive dyskinesias in young people with psychoses [see comments]. Br J Psychiatry 1995; 166:768–772.
57. Comment in: Br J Psychiatry 1995; 167:410–411.
58. Priori A, Bertolasi L, Berardelli A, Manfredi M. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151(12):1819–1821.
59. Raja M, Azzoni A. Novel antipsychotics and acute dystonic reactions. Pharmacol Biochem Behav 2000; 67(3):497–500.
60. Raja M. Tardive dystonia: Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 299 acute psychiatric inpatients. Eur Arch Psychiatry Clin Neurosci 1995; 245:145–151.
61. Sachdev P. The prevalence of tardive dystonia in patients with chronic schizophrenia (letter). Austral N Z J Psychiatry 1991; 25:446–448.
62. Sachdev P. Risk factors for tardive dystonia: A case-control comparison with tardive dyskinesia. Acta Psychiatr Scand 1993a; 88:98–103.
63. Sachdev P. Tardive and chronically recurrent oculogyric crises. Move Disord 1993b; 8(1):93–97.
64. Saran BM. Risperidone induced tardive dyskinesia. J Clin Psychiatry 1998; 59: 29–30.
65. Sethi KD, Adams RJM, Loring DW, El Gammal T. Hallervorden-Spatz syndrome: Clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24: 692–694.
66. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Move Disord 1990; 5:319–321.
67. Suzuki T, Koizumi J, Moroji T, Sakuma K, Hori M, Hori T. Clinical characteristics of the Pisa syndrome. Acta Psych Scand 1990; 82:454–457.
68. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): Epidemiology and management. CNS Drugs 2002; 16:165–174.
69. Tachikawa H, Suzuki T, Kawanishi Y, Hori M, Hori T, Shiraishi H. Tardive dystonia provoked by concomitantly administered risperidone. Psychiatry Clin Neurosci 2000; 54:503–505.
70. Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry 2000; 68:186–190.
71. Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001; 70:557–559.
72. Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine. Mov Disord 1994; 4:441–446.
73. Van Harten PN, Trier Van JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neurolepic-induced acute dystonia. Am J Psychiatry 1986 Jun; 143(6): 706–710.
74. Van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: 1. Schizophr Res 1996; 19:195–203.
75. Van Harten PN, Kamphus DJ, Matroos GF. Use of clozapine in tardive dystoria. Prog Neuro-Psychopharmacol & Biol Psychiat 1996; 20:263–274.
76. Van Putten T, Wirshing WC, Marder SR. Tardive merge syndrome responsive to clozapine. J Psychopharmacol 1990; 10:381–382.
77. Waugh WH, Metts JC. Severe extrapyramidal motor activity induced by prochlorperazine: Its relief by the intravenous injection of diphenhydramine. N. Engl. J. Med 1960; 262:353–354.
78. Winslow RS, Stillner V, Coons DJ, Robison MW. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry 1986; 143:706–710.
79. Wojcik JD, Falk WE, Fink JS, Cole JO, Gelenberg AJ. A review of 32 cases of tardive dystonia [see comments]. Am J Psychiatry 1991; 148:1055–1059.
80. Yassa R, Nair V, Dimitry R. Prevalence of tardive dsytonia. Acta Psychiatr Scand 1986; 73:629–633.
81. Yoshida K, Takahashi H, Sato K, Higuchi H, Shimizu T. Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus. Pharmacol Biochem Behav 2000; 67:497–500.
82. Comment in: Am J Psychiatry 1992; 149:1124–1125.